Recent Updates — HROW

Harrow completed the acquisition of worldwide commercialization rights to TYRVAYA (varenicline solution) nasal spray from Viatris, excluding Japan. Harrow paid $30 million in cash at closing and is obligated to pay up to $70 million in contingent milestone payments based on net sales thresholds through December 2029. The deal adds a differentiated, drop-free treatment option for dry eye disease to Harrow's portfolio, complementing its existing product VEVYE. Approximately 40 personnel from Viatris are expected to join Harrow's commercial team in the fourth quarter of 2026. Harrow expects TYRVAYA to contribute more than $30 million in revenue in 2027. Harrow is a leading provider of ophthalmic disease management solutions in North America.

Harrow, Inc. reported second quarter 2026 financial results with total revenue of $70.7 million, an increase of 11% year over year and 60% sequentially. The company posted a GAAP net loss of $17.3 million and Adjusted EBITDA of negative $1.2 million for the quarter. Harrow reiterated its full-year 2026 guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA. Key product highlights included VEVYE revenue of $29.4 million, up approximately 58% year over year, and IHEEZO unit demand reaching a record 65,477 units, up 34% year over year. The company announced the acquisition of TYRVAYA from Viatris, expected to close in the second half of 2026, and launched BYOOVIZ, a biosimilar to LUCENTIS. Harrow holds $83.9 million in cash as of June 30, 2026. The company operates in the ophthalmic disease management industry, providing pharmaceutical solutions for conditions affecting the front and back of the eye.